Product
Pyronaridine- artesunate (Pyramax)
1 clinical trial
1 indication
Indication
MalariaClinical trial
Phase IIa Proof of Concept, Multicenter, Randomized, Open-label Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of the Combination M5717 Plus Pyronaridine Administered Once Daily for 1 or 2 Days to Adults and Adolescents With Acute Uncomplicated Plasmodium Falciparum Malaria (CAPTURE 1)Status: Recruiting, Estimated PCD: 2024-09-18